Clinical Trial Update: Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating RSD1235-SR for preventing recurrence of atrial fibrillation and atrial flutter has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• RSD1235-SR

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED